Technological advances in the monitoring of glucose and dosing of insulin for diabetes patients has led JP Morgan analyst Robbie Marcus to upgrade shares of Dexcom to "overweight" and raise his price target on the firm from $80 to $115. US firm Dexcom makes continuous glucose monitoring devices (CGM) that attach to a patient's skin, and treatment is moving in the direction of integrated pumps that link insulin dosage to CGMs, Marcus said. Dexcom's system also provides tools that connect to phones and share data with treatment providers, CEO Kevin Sayer explained. Erin Black New technologies for diabetes treatment are becoming essential for those who suffer from the disease, according to J.P. Morgan, and that could make companies such as Dexcom compelling investment opportunities. The company said it expects sales growth this year at its medical device business as more people use their smartphones or tablets to monitor blood sugar levels.
Technological advances in the monitoring of glucose and dosing of insulin for diabetes patients has led JP Morgan analyst Robbie Marcus to upgrade shares of Dexcom to "overweight" and raise his price target on the firm from $80 to $115. US firm Dexcom makes continuous glucose monitoring devices (CGM) that attach to a patient's skin, and treatment is moving in the direction of integrated pumps that link insulin dosage to CGMs, Marcus said. Dexcom's system also provides tools that connect to phones and share data with treatment providers, CEO Kevin Sayer explained. The company said it expects sales growth this year at its medical device business as more people use their smartphones or tablets to monitor blood sugar levels.